GBA Presents: RADIO SAVANT-!

[stonedinvestor]

Ston, EPIX or too late? $3.38.

It still looks good to me.

Additional Essa EPI-7386 data supports combination potential, says Piper Sandler 10:26 EPIX Piper Sandler analyst Joseph Catanzaro notes that Essa Pharma announced updated clinical data from the first two cohorts of the Phase I/II study of EPI-7386 in combination with enzalutamide in patients with mCRPC. The combination regimen showed deep efficacy, with 5/6 evaluable patients achieving a PSA90 response. The data also provides clarity that will allow for optimal dosing, with PK results and safety showing room for the full dose of enz as well as the higher 600 mg BID dose of EPI-7386 that will be tested in the next dose cohorts, Catanzaro adds. Overall, a strong efficacy signal that was achieved at sub-maximal dosing validates the combination dosing strategy, in his view.

$4.17 you can buy more here

 

[stonedinvestor]

Stoney do you and Big Pete still own Arch Coal?
They missed eps, but beat revenue handily. These companies are all beating on the top and missing on the bottom.
That's rising costs of benefits and wages.
I doubt the Fed will back off of another .75 hike this time.

I unfortunately dipped on the coal stks. Mistake. In retrospect.
Big Pete is big into Danbury Res.... I think he folded all his coal eggs int that basket.
risky but he probably knows something.

 

[stonedinvestor]

Vaccination maker PCVX? Took out $42 yesterday with great $40-$45 call volume.

Jesus did they spike after a secondary

Vaxcyte 15M share Secondary priced at $32.00 06:06 PCVX The deal priced below last closing price of $34.86. Needham and BTIG are acting as joint book running managers for the offering.

 

[stonedinvestor]

Ok Heads Up Sometimes a stock moves and we don't see it.

MRNA <--- Big Freakin' Alert ** I let this one go cleaning up the old portfolio here-
we had this at $133.

Moderna, Inc. (MRNA) Hello!!!! 5 days $126-----> $144!!! What's UP!!!!!
NasdaqGS - NasdaqGS Real Time Price.
144.11+2.11(+1.49%)
At close: 04:00PM EDT
Nobody is getting their booster shot. This cannot be good for MODERNA.
If the virus kicks us in the ass this winter it will be better for Moderna.

Until then I think the Gov is about to give them a large contract for something else.

Now $147

 

[stonedinvestor]

Horse Face looks worried van.

 

[stonedinvestor]

Glatfelter Corporation (GLT)
NYSE - Nasdaq Real Time Price.
2.9650+0.1750 (+6.27%)
As of 12:38PM EDT.

 

[stonedinvestor]

Keep Track Of This-! // Not in yet.

Stoke Therapeutics, Inc. (STOK)
NasdaqGS - NasdaqGS Real Time Price.
14.80+0.51(+3.57%)
As of 12:06PM EDT. Market open.

Stoke Therapeutics, Inc. (STOK)---BUY!
NasdaqGS - NasdaqGS Real Time Price.
16.43+0.92(+5.93%)<------------------------
As of 12:41PM EDT.

 

[stonedinvestor]

Federal Signal Corporation (FSS)
NYSE - Nasdaq Real Time Price.
46.62+1.44(+3.19%)<------------------
As of 12:42PM EDT.

 

[stonedinvestor]

GBA UPGRADE STRYKER!- $210

Stryker initiated with a Buy at Jefferies 09:18 SYK Jefferies analyst Matthew Taylor initiated coverage of Stryker with a Buy rating and $270 price target. In a note on the group, Taylor and peers noted that MedTech sentiment has been "flagging" given how procedures have recovered in fits and starts amid lingering COVID headwinds. However, Taylor, Young Li and Michael Sarcone think "the tide could be turning" as recent data points suggest macro challenges are stable to improving, the trio state in their note initiating coverage on the Medical Supplies & Devices group.

Children gather round. Just because Uncle Stoney sells a stock doesn't mean you should forget what fine work that stock has done for you.

Stryker Corporation (SYK)--SOLD-! $20 Trade!!!!!!!!!!!!!
NYSE - Nasdaq Real Time Price.
230.66+2.38(+1.04%)
As of 12:45PM EDT. Market open.

• GBA TRADE: (SYK) $210-------> $230.50

 

[TrailerParkTed]

It still looks good to me.

Additional Essa EPI-7386 data supports combination potential, says Piper Sandler 10:26 EPIX Piper Sandler analyst Joseph Catanzaro notes that Essa Pharma announced updated clinical data from the first two cohorts of the Phase I/II study of EPI-7386 in combination with enzalutamide in patients with mCRPC. The combination regimen showed deep efficacy, with 5/6 evaluable patients achieving a PSA90 response. The data also provides clarity that will allow for optimal dosing, with PK results and safety showing room for the full dose of enz as well as the higher 600 mg BID dose of EPI-7386 that will be tested in the next dose cohorts, Catanzaro adds. Overall, a strong efficacy signal that was achieved at sub-maximal dosing validates the combination dosing strategy, in his view.

$4.17 you can buy more here

They hit $5.80 in AH the same day, I did ok buying cheap $5c and a few thousand. Today DVA, shorted $74 and $70 puts(20) covered $70.10 and out above $2.75. Than Apple 0DTE $155c bought $.15-.20s, out $1.50+, Fun day!